Reneo Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Reneo Pharmaceuticals's estimated annual revenue is currently $10.4M per year.(i)
  • Reneo Pharmaceuticals's estimated revenue per employee is $155,000

Employee Data

  • Reneo Pharmaceuticals has 67 Employees.(i)
  • Reneo Pharmaceuticals grew their employee count by 29% last year.

Reneo Pharmaceuticals's People

NameTitleEmail/Phone
1
Head, Global Patient AdvocacyReveal Email/Phone
2
SVP Finance & AdministrationReveal Email/Phone
3
VP, Market Access & PolicyReveal Email/Phone
4
SVP, Translational ScienceReveal Email/Phone
5
VP - Corporate OperationsReveal Email/Phone
6
VP, Global Tech Ops & CMCReveal Email/Phone
7
VP Health Economics and Outcomes ResearchReveal Email/Phone
8
SVP, Human ResourcesReveal Email/Phone
9
Head, US Medical Science LiaisonsReveal Email/Phone
10
VP Clinical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Reneo Pharmaceuticals?

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting. We are currently advancing a novel molecule into several diseases. Our experienced team of drug development experts, who have collaborated in many successful programs, are dedicated and passionate about finding effective therapies for these complex rare diseases.

keywords:N/A

N/A

Total Funding

67

Number of Employees

$10.4M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Reneo Pharmaceuticals News

2022-03-30 - vTv Therapeutics Announces 2021 fourth Quarter and Full ...

... HPP737) and Reneo Pharmaceuticals, Inc (with respect to HPP593). ... in the fair value of our investment in Reneo as well as the gains...

2022-03-22 - Reneo Pharmaceuticals Reports Fourth Quarter and Full Year ...

IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company...

2022-03-22 - SVB Leerink Maintains Outperform on Reneo Pharmaceuticals, Lowers Price Target to $15 - Benzinga

SVB Leerink Maintains Outperform on Reneo Pharmaceuticals, Lowers Price Target to $15 ... This headline-only article is meant to show you why a...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.4M67-9%N/A
#2
$8.5M67-9%N/A
#3
$8.7M6710%N/A
#4
$13.3M67N/AN/A
#5
$10.4M6737%N/A